Alan Freeman, MD
Neurology · Atlanta, GANPI 1124132766
Payments from drug & device makers
Across 21 payments — averaging $874.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MDD US Operations, LLC$18K
- GE HealthCare$40
- Merz Pharmaceuticals, LLC$19
Across 3 payments — averaging $4884.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurocrine Biosciences, Inc.$15K
What the payments were for
- Food & beverage$58100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MDD US Operations, LLC | 18 | $18,314 |
| GE HealthCare | 2 | $40 |
| Merz Pharmaceuticals, LLC | 1 | $19 |
How this compares
$18,372 in reported general payments places this provider in the 80th percentile of 506 neurology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 11 | $388,536 |
| AustedoDeutetrabenazine | 12 | $157,878 |
| NuplazidPimavanserin Tartrate | 28 | $137,868 |
| IngrezzaValbenazine Tosylate | 12 | $101,323 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 599 | $31,313 |
| RytaryCarbidopa/Levodopa | 13 | $30,797 |
| NeuproRotigotine | 18 | $17,912 |
| Entacapone | 45 | $8,699 |
| Rasagiline Mesylate | 56 | $8,655 |
| Rivastigmine | 37 | $8,033 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 162 | $6,258 |
| AmantadineAmantadine Hcl | 100 | $4,858 |
| Primidone | 100 | $4,783 |
| Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone | 24 | $4,262 |
| Selegiline Hcl | 23 | $2,023 |
Paid to pharmacies, not to this prescriber.
Other neurology in Atlanta
- James LahAtlanta$6.8M
- Jonathan GlassAtlanta$5.1M
- Allan LeveyAtlanta$4.2M
- Ben ThrowerAtlanta$3.7M
- Jeffrey EnglishAtlanta$3.1M
- Dennis LaceyAtlanta$2.8M
- Julio FlaminiAtlanta$1.6M
- Joash LazarusAtlanta$1.4M
- Frank BerensonAtlanta$1.2M
- Stewart FactorAtlanta$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.